公募基金方面，本期较上一季度新披露的公募基金共计3个，包括中欧悦享生活混合A、中欧行业景气 一年持有混合A、中欧行业鑫选混合A。本期较上一季未再披露的公募基金共计49个，主要包括广发价 值核心混合A、华夏行业景气混合A、泉果旭源三年持有期混合A、华夏高端制造混合A、万家成长优选 混合A等。 2025年10月30日，博拓生物(688767.SH)发布2025年第三季报。截至2025年10月29日，共有7个机构投资 者披露持有博拓生物A股股份，合计持股量达5778.70万股，占博拓生物总股本的38.70%。其中，机构 投资者包括杭州拓康投资有限公司、杭州康宇企业管理咨询合伙企业(有限合伙)、杭州博拓生物科技股 份有限公司-2024年员工持股计划、中欧悦享生活混合A、富国积极成长一年定期开放混合、中欧行业 景气一年持有混合A、中欧行业鑫选混合A，机构投资者合计持股比例达38.70%。相较于上一季度，机 构持股比例合计下跌了5.35个百分点。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688767 证券简称：博拓生物 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈 述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 注1："本报告期"指本季度初至本季度末3个月期间，下同。 注2：2025年6月，公司实施2024年年度权益分派，向全体股东每10股以资本公积金转增4股，共转增 42,666,667股。公司按调整后的股数重新计算上年同期基本每股收益、稀释每股收益。 （二） 非经常性损益项目和金额 √适用 □不适用 （三） 主要会计数据、财务指标发生变动的情况、原因 √适用 □不适用 二、 股东信息 （一） 普通股股东总数和表决权恢复 ...

格隆汇10月29日丨博拓生物(688767.SH)发布三季报，2025年前三季度实现营业总收入3.08亿元，同比下 降20.76%；归属母公司股东净利润2226.32万元，同比下降75.04%；基本每股收益为0.14元。 ...

证券代码：688767 证券简称：博拓生物 公告编号：2025-042 杭州博拓生物科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要提示： 上海证券交易所上证路演中心上海证券交易所上证路演中心 投资者可于 2025 年 11 月 6 日（星期四）至 11 月 12 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir.secretary@biotests.com.cn 进行提问，公司将在说明会上对投资者普遍关 注的问题进行回答。 一、说明会类型 杭州博拓生物科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日在上海证券交易所网站（www.sse.com.cn）披露公司 2025 年第三季度报告， 为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况， 公司计划于 2025 年 11 月 13 日上午 9:00-10:00 举行 2025 年第三季度业绩说明 会，就投资者关 ...

杭州博拓生物科技股份有限公司 2025 年第三季度报告 杭州博拓生物科技股份有限公司2025 年第三季度报告 证券代码：688767 证券简称：博拓生物 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 1 / 16 杭州博拓生物科技股份有限公司2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 | | | | 单位：元 | 币种：人民币 | | --- | --- | --- | --- | --- | | | | 本报告期比 | | 年初至报告期 | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | ...

博拓生物公告，第三季度营收为1.05亿元，下降13.84%；净利润为986.09万元，下降42.12%。前三季度 营收为3.08亿元，下降20.76%；净利润为2226.32万元，下降75.04%。 ...

10月29日，博拓生物涨5.46%，截至发稿，报46.20元/股，成交1.04亿元，换手率1.56%，总市值68.99亿 元。 资料显示，杭州博拓生物科技股份有限公司位于浙江省杭州市余杭区仓前街道途义路27号，成立日期 2008年11月28日，上市日期2021年9月8日，公司主营业务涉及从事POCT诊断试剂的研发、生产和销 售。主营业务收入构成为：POCT产品业务及其他100.00%。 从基金十大重仓股角度 数据显示，富国基金旗下1只基金重仓博拓生物。富国积极成长一年定期开放混合（009693）三季度持 有股数61.38万股，占基金净值比例为4.27%，位居第九大重仓股。根据测算，今日浮盈赚取约146.69万 元。 富国积极成长一年定期开放混合（009693）成立日期2020年6月15日，最新规模5.78亿。今年以来收益 64.11%，同类排名525/8155；近一年收益63.45%，同类排名484/8031；成立以来收益90.24%。 富国积极成长一年定期开放混合（009693）基金经理为杨栋、孟浩之。 截至发稿，杨栋累计任职时间10年76天，现任基金资产总规模98.09亿元，任职期间最佳基金回报 329. ...

Market Performance - The medical device sector increased by 1.01% on October 21, with Botao Bio leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Top Gainers - Botao Bio (688767) closed at 43.39, up 8.12% with a trading volume of 50,200 shares and a transaction value of 216 million [1] - Xiangsheng Medical (688358) closed at 34.93, up 6.62% with a trading volume of 45,600 shares and a transaction value of 157 million [1] - Hualan Biological (301093) closed at 39.30, up 6.53% with a trading volume of 57,500 shares and a transaction value of 223 million [1] Top Losers - Jinhao Medical (920925) closed at 31.85, down 2.24% with a trading volume of 11,900 shares and a transaction value of 37.83 million [2] - Toukeng Life (300642) closed at 26.75, down 2.01% with a trading volume of 162,300 shares and a transaction value of 44.4 million [2] - Maillande (688273) closed at 40.48, down 1.99% with a trading volume of 22,300 shares and a transaction value of 90.15 million [2] Capital Flow - The medical device sector experienced a net outflow of 229 million from institutional investors and 168 million from retail investors, while retail investors saw a net inflow of 397 million [2][3] - Notable capital inflows included Xinhua Medical with a net inflow of 24.93 million from institutional investors [3] - Hualan Biological had a net inflow of 20.37 million from institutional investors, despite a net outflow from retail investors [3]

Core Viewpoint - The flu-related stocks experienced a significant surge on October 21, with notable increases in companies such as Te Yi Pharmaceutical, Jinshi Yao, and Hualan Vaccine, driven by rising flu activity in southern China and predictions of an earlier flu season this year [1][4]. Group 1: Stock Performance - Te Yi Pharmaceutical reached a trading limit with a price of 10.27, reflecting a 9.96% increase [2] - Jinshi Yao saw a price increase to 11.73, marking a 15.11% rise [2] - Hualan Vaccine's stock rose to 22.15, showing an 11.87% increase [2] - New Ganjing's stock price increased to 23.72, with a rise of 11.41% [2] - Other companies like Hengdi Pharmaceutical and Xiangrikui also followed the upward trend [1]. Group 2: Flu Activity and Predictions - The China CDC reported an increase in flu activity in southern provinces, indicating a potential early onset of the flu season this year [4] - Experts noted that the predominant flu strain this year is H3N2, differing from last year's H1N1 strain, which may lead to lower immunity levels in the population [5]. Group 3: Vaccination Recommendations - Vaccination is emphasized as the most effective method to prevent flu and reduce severe cases, with recommendations for individuals to get vaccinated between September and November [8] - The flu vaccine needs to be administered annually due to the rapid mutation of the virus, ensuring protection against the current year's strains [8][9]. - High-risk groups, including children under 5, the elderly, and individuals with chronic health conditions, are advised to prioritize vaccination [12].

Core Viewpoint - The article highlights the rising flu activity in southern China, with predictions of an earlier flu season this year compared to last, primarily driven by the different circulating strain, H3N2, which the public has lower immunity against [2][3]. Group 1: Flu Activity and Strain Information - The current flu season is characterized by the predominance of the H3N2 strain, contrasting with last year's H1N1 strain, indicating a need for heightened awareness due to lower public immunity [3]. - Clinical symptoms of H3N2 include high fever, cough, sore throat, body aches, fatigue, and headache, which are similar to other flu strains [3]. Group 2: Vaccination Recommendations - Vaccination is emphasized as the most effective method to prevent flu and reduce severe cases, with the recommended vaccination period being from September to November to ensure immunity before peak season [5]. - Annual vaccination is necessary due to the rapid mutation of flu viruses, which may differ from year to year, thus requiring updated protection [6]. - High-risk groups, including children under 5, the elderly over 65, pregnant women, and those with chronic health conditions, are advised to receive vaccinations promptly [10]. Group 3: Vaccine Types and Administration - The available flu vaccines in China include inactivated (split) vaccines (trivalent/quadrivalent), inactivated (subunit) vaccines (trivalent/quadrivalent), and live attenuated vaccines (trivalent, nasal spray) [8]. - The difference between trivalent and quadrivalent vaccines lies in the number of virus strains they protect against, with quadrivalent covering an additional B strain, although the practical effectiveness may not differ significantly [8].